Tonix Pharmaceuticals Announces 1-for-32 Reverse Stock Split CHATHAM, N.J.

TONIX PHARMACEUTICALS HOLDING CORP. 8-K

Tonix Pharmaceuticals Announces 1-for-32

CHATHAM, N.J., May 16, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals

Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that it will effect a

1-for-32 reverse stock split of its outstanding common stock. This will be effective for trading purposes as of the commencement of trading

The reverse stock split was previously approved by the Board of Directors

of Tonix in accordance with Nevada law, under which no stockholder approval is required, and is intended to increase the per share trading

price of Tonix's common stock to satisfy the $1.00 minimum bid price requirement for continued listing on The NASDAQ Capital Market

(Rule 5550(a)(1)). Tonix's common stock will continue to trade on the NASDAQ Capital Market under the symbol "TNXP"

and under a new CUSIP number, 890260862. As a result of the reverse stock split, every thirty-two pre-split shares of common stock outstanding

will become one share of common stock. The reverse stock split will also proportionately reduce the number of shares of authorized common

stock from 1,600 million to 50 million shares. The reverse split will also apply to common stock issuable upon the exercise of Tonix's

outstanding warrants and stock options.

Tonix's transfer agent, VStock Transfer LLC, which is also acting

as the exchange agent for the reverse split, will provide instructions to shareholders regarding the process for exchanging share certificates.

Any fractional shares of common stock resulting from the reverse stock split will be rounded up to the nearest whole post-split share

and no shareholders will receive cash in lieu of fractional shares.

About Tonix Pharmaceuticals Holding Corp.1

Tonix is a clinical-stage biopharmaceutical company

focused on discovering, licensing, acquiring and developing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's

portfolio is composed of central nervous system (CNS), rare disease, immunology and infectious disease product candidates. Tonix's

CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix's

lead CNS candidate, TNX-102 SL (cyclobenzaprine HCl sublingual tablet), is in mid-Phase 3 development for the management of fibromyalgia

with a new Phase 3 study launched in the second quarter of 2022 and interim data expected in the first quarter of 2023. TNX-102 SL is

also being developed to treat Long COVID, a chronic post-acute COVID-19 condition. Tonix expects to initiate a Phase 2 study in Long COVID

in the second quarter of 2022. TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication that is expected

to start a Phase 2 trial in the second quarter of 2022. TNX-1300 has been granted Breakthrough Therapy Designation by the FDA. Finally,

TNX-1900 (intranasal potentiated oxytocin), a small molecule in development for chronic migraine, is expected to enter the clinic with

a Phase 2 study in the second half of 2022. Tonix's rare disease portfolio includes TNX-2900 (intranasal potentiated oxytocin)

for the treatment of Prader-Willi syndrome. TNX-2900 has been granted Orphan-Drug Designation by the FDA. Tonix's immunology portfolio

includes biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500 which is a humanized monoclonal

antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune

diseases. A Phase 1 study of TNX-1500 is expected to be initiated in the second half of 2022. Tonix's infectious disease pipeline

consists of a vaccine in development to prevent smallpox and monkeypox called TNX-801, next-generation vaccines to prevent COVID-19, and

a platform to make fully human monoclonal antibodies to treat COVID-19. Tonix's lead vaccine candidates for COVID-19 are TNX-1840

and TNX-1850, which are live virus vaccines based on Tonix's recombinant pox live virus vector vaccine platform.

product candidates are investigational new drugs or biologics and have not been approved for any indication.

This press release and further information about

Tonix can be found at www.tonixpharma.com.

Forward Looking Statements

Certain statements in this press release are forward-looking within

the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking

words such as "anticipate," "believe," "forecast," "estimate," "expect," and

"intend," among others. These forward-looking statements are based on Tonix's current expectations and actual results could

differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking

statements. These factors include, but are not limited to, risks related to the reverse stock split, failure to obtain FDA clearances

or approvals and noncompliance with FDA regulations; delays and uncertainties caused by the global COVID-19 pandemic; risks related to

the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent

protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and

dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks

in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise

any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December

31, 2021, as filed with the Securities and Exchange Commission (the "SEC") on March 14, 2022, and periodic reports filed with

the SEC on or after the date thereof. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other

cautionary statements. The information set forth herein speaks only as of the date thereof.

Jessica Morris (corporate)

Tonix Pharmaceuticals

Olipriya Das, Ph.D. (media)

Peter Vozzo (investors)